Atypical presentation of moyamoya disease with pulmonary hypertension: A case report

References (2)

1. Day RW, Brockmeyer DL, Feola GP. Safe treatment of pulmonary hypertension with bosentan in a patient with moyamoya disease and cerebral ischemia. J Child Neurol 2010; 25: 504-7. [CrossRef] Tokunaga K, Hishikawa T, Sugiu K, Date I. Fatal outcomes of pediatric patients with moyamoya disease associated with pulmonary arterial hypertension. Report of two cases. Clin Neurol Neurosurg 2013: 115; 335-8. [CrossRef] Ou P, Dupont P, Bonnet D. Fibromuscular dysplasia as the substrate for systemic and pulmonary hypertension in the setting of Moya-Moya disease. Cardiol Young 2006; 16: 495-7. [CrossRef] Kapusta L, Daniëls O, Renier WO. Moya-Moya syndrome and primary pulmonary hypertension in childhood. Neuropediatrics 1990: 21; 162-3.
2. Fukushima H, Takenouchi T, Kosaki K. Homozygosity for moyamoya disease risk allele leads to moyamoya disease with extracranial systemic and pulmonary vasculopathy. Am J Med Genet A 2016; 170: 2453-6. [CrossRef] Amlie-Lefond C, Ellenbogen RG. Factors Associated with the Presentation of Moyamoya in Childhood. J Stroke Cerebrovasc Dis 2015; 24: 1204-10. [CrossRef] Fukui M. Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis ('moyamoya' disease). Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) of the Ministry of Health and Welfare, Japan. Clin Neurol Neurosurg 1997; 99(Suppl 2): S238-40. [CrossRef] Natori Y, Ikezaki K, Matsushima T, Fukui M. “Angiographic moyamoya” its definition, classification, and therapy. Clin Neurol Neurosurg 1997; 99(Suppl 2): S168-72. [CrossRef] Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-30. [CrossRef]